Targeting IKKβ for the treatment of rheumatoid arthritis.
Bamborough
Paul
P
GlaxoSmithKline R&D, Medicines Research Centre, Stevenage, Hertfordshire, UK. paul.a.bamborough@gsk.com
Morse
Mary A
MA
Ray
Keith P
KP
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D051550:I-kappa B Kinase